Dec 23, 2019
Global Therapeutic Proteins Market Report 2020: Market was Valued at $93.14 Billion in 2018 and is Expected to Grow to $172.87 Billion through 2022 - ResearchAndMarkets.com
Dec 12, 2019
Soligenix Initiates Clinical Trial of its Heat Stable Ricin Toxin Vaccine
Nov 27, 2019
Protalix BioTherapeutics Hosting Key Opinion Leader Meeting on PRX-102 Drug Candidate for the Treatment of Fabry Disease
Nov 18, 2019
WuXi Biologics Congratulates Tychan on the World's First Yellow Fever Antibody Tested Safe and Efficacious in Human Volunteers
Nov 06, 2019
Ervaxx Launches to Pioneer the Use of Dark Antigens(TM) for the Development of Off-the-Shelf Cancer Vaccines and T-cell Receptor-based Immunotherapies
Oct 22, 2019
Chugai Renews License to EpiVax's ISPRI In Silico Toolkit for Immunogenicity Assessment
Sep 30, 2019
Rakuten Medical Releases New, Post-hoc Analysis of Safety, Pharmacokinetic (PK), Immunogenicity and Biomarker Data from its Phase 1 & 1/2a Clinical Trials
Aug 08, 2019
Provention Bio Initiates Phase 1b/2a PREVAIL Clinical Trial Evaluating PRV-3279 in Lupus
Jul 10, 2019
Geneos Therapeutics Announces First Patient Dosed with its DNA-based, Neoantigen-Targeting Personalized Vaccine Technology
Mar 25, 2019
EpiVax Oncology To Present Latest Research On The Importance Of Identifying And Removing, Using Machine-Learning Based Advanced Computational Tools, Inhibitory Neoantigens From Therapeutic Cancer Vaccines, At AACR Annual Meeting 2019
Mar 21, 2019
Inovio's Ebola Vaccine Delivered Intradermally Demonstrates 100% Immunogenicity in a Clinical Study Published in The Journal of Infectious Diseases
Feb 25, 2019
ABL Bio Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody(TM) Platform for Novel Immune Check Point Bispecifics for $220 Million
Feb 04, 2019
VLP Therapeutics to Initiate First Clinical Trial of VLPM01 Malaria Vaccine
Jan 16, 2019
United Neuroscience Announces Positive Top-Line Results from Phase 2a Clinical Study of UB-311 Vaccine in Patients with Alzheimer's Disease
Oct 02, 2018
Office of Generic Drugs (OGD/FDA) Awards $1M FDA Contract to CUBRC and EpiVax for Demonstration and Validation of Immunogenicity Risk Assessment Methods for Generic Peptide Drugs and Their Impurities
Aug 21, 2018
Switching to CRISPR: Detailed Understanding of the Two Major Types of Adaptive Immunity to Cas9 Proteins - Humoral Immunity and Cell-Mediated Immunity
Aug 21, 2018
Initiation of Biosceptre's Phase 1 Clinical Trial for First-in-Class Oncology Vaccine BIL06v
May 11, 2018
Epic Sciences Presents Detection and Characterization of Rare Peripheral CTC Immunogenicity and T-Cell Activation
Mar 28, 2018
Meissa Vaccines' Cofounder and CEO Dr. Martin Moore to Present at World Vaccine Congress
Mar 27, 2018
PharmaJet to present latest Research Results at World Vaccine Congress